154 related articles for article (PubMed ID: 38876049)
1. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone.
Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R
Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049
[TBL] [Abstract][Full Text] [Related]
2. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
5. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
Collins BF; Raghu G
Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
9. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts.
Meng C; Fan G; Liu J; Tao N; Sun T
Biochem Biophys Res Commun; 2024 Jul; 716():150020. PubMed ID: 38692011
[TBL] [Abstract][Full Text] [Related]
11. MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis.
Boehme SA; Franz-Bacon K; DiTirro DN; Ly TW; Bacon KB
PLoS One; 2016; 11(5):e0154874. PubMed ID: 27144281
[TBL] [Abstract][Full Text] [Related]
12. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
13. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
[TBL] [Abstract][Full Text] [Related]
14. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Moodley Y; Corte T; Richeldi L; King TE
Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
[TBL] [Abstract][Full Text] [Related]
15. Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.
Ronan N; Bennett DM; Khan KA; McCarthy Y; Dahly D; Bourke L; Chelliah A; Cavazza A; O'Regan K; Moloney F; Plant BJ; Henry MT
Lung; 2018 Oct; 196(5):543-552. PubMed ID: 30066212
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
[TBL] [Abstract][Full Text] [Related]
17. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
18. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
19. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
